Molecular structure of Erismodegib, CAS Number: 956697-53-3
Erismodegib (CAS 956697-53-3)
Alternate Names:
NVP-LDE225; LDE225
Application:
Erismodegib is a selective Smo (Smoothened) antagonist
CAS Number:
956697-53-3
Molecular Weight:
485.50
Molecular Formula:
C26H26F3N3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Erismodegib utilized as a tool to investigate the molecular mechanisms of signal transduction related to the Hedgehog signaling pathway, which plays a role in cellular communication and development. Research involving Erismodegib often focuses on its binding affinity and inhibitory effects on the protein smoothened (SMO), which is a component of this signaling cascade. The precise binding interaction of Erismodegib with SMO helps researchers understand the modulation of this pathway at a detailed level. Moreover, the compound′s effects on the Hedgehog pathway have made it a point of interest in the study of cellular processes during developmental stages and in various cellular conditions.
Erismodegib (CAS 956697-53-3) References
- Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. | Wang, J., et al. 2012. Bioorg Med Chem. 20: 6751-7. PMID: 23063522
- NPV-LDE-225 (Erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. | Fu, J., et al. 2013. Neuro Oncol. 15: 691-706. PMID: 23482671
- NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. | Nanta, R., et al. 2013. Oncogenesis. 2: e42. PMID: 23567619
- Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. | Heinemann, V., et al. 2014. Cancer Treat Rev. 40: 118-28. PMID: 23849556
- Novel myelofibrosis treatment strategies: potential partners for combination therapies. | Stein, BL., et al. 2014. Leukemia. 28: 2139-47. PMID: 24888274
- Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. | D'Amato, C., et al. 2014. Br J Cancer. 111: 1168-79. PMID: 25093491
- The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. | Tibes, R., et al. 2015. J Hematol Oncol. 8: 114. PMID: 26483188
- Identification of Small Molecules Which Induce Skeletal Muscle Differentiation in Embryonic Stem Cells via Activation of the Wnt and Inhibition of Smad2/3 and Sonic Hedgehog Pathways. | Lee, H., et al. 2016. Stem Cells. 34: 299-310. PMID: 26577380
- Bromodomain and hedgehog pathway targets in small cell lung cancer. | Kaur, G., et al. 2016. Cancer Lett. 371: 225-39. PMID: 26683772
- Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment. | Zhang, H., et al. 2016. Oncotarget. 7: 14350-65. PMID: 26885608
- Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. | Bansal, R., et al. 2017. Exp Mol Med. 49: e396. PMID: 29147013
- Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer. | Kowolik, CM., et al. 2019. J Exp Clin Cancer Res. 38: 431. PMID: 31661013
- Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study. | Ottmann, OG., et al. 2021. Leuk Lymphoma. 62: 739-742. PMID: 33153366
- Pathways in small cell lung cancer and its therapeutic perspectives. | Shivapriya, PM., et al. 2021. Front Biosci (Landmark Ed). 26: 1668-1678. PMID: 34994180
- Finding alternatives to 5-fluorouracil: application of ensemble-based virtual screening for drug repositioning against human thymidylate synthase. | Mteremko, D., et al. 2022. J Biomol Struct Dyn. 1-17. PMID: 35538714
Inhibitor of:
APCDD1L, ASCL1, C1orf53, C2CD3, CELSR1, DAND5, DCHS2, DISP1, DISP2, Gas1, GUP1, HATH-1, HDRP, hedgehog, HH, HHIPL1, HHIPL2, Ihh, INTU, KCTD7, KIAA1822L, LELP1, MACS1, MESP2, Olr1217, patched, patched 2, PTCHD1, PTCHD2, PTCHD3, PTCHD4, Shh, Slit3, Smo, STK36, Su(fu), TMEM218, and VAX1.Activator of:
cubitus interruptus, DISP2, EVC2, GLI-1, Hhip, IFT172, and Smo.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Erismodegib, 10 mg | sc-396280 | 10 mg | $255.00 | |||
Erismodegib, 100 mg | sc-396280A | 100 mg | $918.00 |